Target family: Voltage-gated calcium channels  (Ca<sub>V</sub>) (type: vgic)
Target: Ca<sub>v</sub>1.3

Ligand: amlodipine (Synthetic organic)
Interaction type: Gating inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1992), EMA (2007)
Primary target: no
Median affinity: 7.199999809265137 pIC50
Reference (Journal): Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms.
Published in: Mol Pharmacol

Ligand: azidopine (Synthetic organic)
Interaction type: Gating inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.199999809265137 pIC50
Reference (Journal): Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms.
Published in: Mol Pharmacol

Ligand: BAYK 8644 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): Neuronal Ca(V)1.3alpha(1) L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridines.
Published in: J Neurosci

Ligand: BAYK 8644 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): Congenital deafness and sinoatrial node dysfunction in mice lacking class D L-type Ca2+ channels.
Published in: Cell

Ligand: BAYK 8644 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): alpha 1D (Cav1.3) subunits can form l-type Ca2+ channels activating at negative voltages.
Published in: J Biol Chem

Ligand: Cd2+ (Inorganic)
Interaction type: Channel blocker
Action: Antagonist
Median affinity:  -
Reference (Journal): Functional expression and characterization of a voltage-gated CaV1.3 (alpha1D) calcium channel subunit from an insulin-secreting cell line.
Published in: Mol Endocrinol

Ligand: cinnarizine (Synthetic organic)
Interaction type: Channel blocker
Action: Pore blocker
Ligand approved: yes
Approval source: UK (1989)
Primary target: no
Median affinity: 5.820000171661377 pIC50
Reference (Journal): Inhibition of voltage-gated calcium currents in type II vestibular hair cells by cinnarizine.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: diltiazem (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1982)
Primary target: no
Median affinity: 3.5 pIC50
Reference (Journal): Effects of phenylalkylamines and benzothiazepines on Ca(v)1.3-mediated Ca2+ currents in neonatal mouse inner hair cells.
Published in: Eur J Pharmacol

Ligand: FPL64176 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.800000190734863 pEC50

Ligand: isradipine (Synthetic organic)
Interaction type: Gating inhibitor
Action: None
Ligand approved: yes
Approval source: FDA (1990)
Primary target: no
Median affinity:  pIC50
Reference (Journal): Lower Affinity of Isradipine for L-Type Ca<sup>2+</sup> Channels during Substantia Nigra Dopamine Neuron-Like Activity: Implications for Neuroprotection in Parkinson's Disease.
Published in: J Neurosci

Ligand: isradipine (Synthetic organic)
Interaction type: Gating inhibitor
Action: None
Ligand approved: yes
Approval source: FDA (1990)
Median affinity:  -
Reference (Journal): alpha 1D (Cav1.3) subunits can form l-type Ca2+ channels activating at negative voltages.
Published in: J Biol Chem

Ligand: nifedipine (Synthetic organic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: no
Median affinity: 7.699999809265137 pIC50
Reference (Journal): Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms.
Published in: Mol Pharmacol

Ligand: nimodipine (Synthetic organic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1988)
Primary target: no
Median affinity:  pIC50
Reference (Journal): Functional properties of Cav1.3 (alpha1D) L-type Ca2+ channel splice variants expressed by rat brain and neuroendocrine GH3 cells.
Published in: J Biol Chem

Ligand: nimodipine (Synthetic organic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1988)
Primary target: no
Median affinity:  pIC50
Reference (Journal): Neuronal Ca(V)1.3alpha(1) L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridines.
Published in: J Neurosci

Ligand: nisoldipine (Synthetic organic)
Interaction type: Gating inhibitor
Action: None
Ligand approved: yes
Approval source: FDA (1995)
Median affinity:  pIC50
Reference (Journal): Enhanced expression of L-type Cav1.3 calcium channels in murine embryonic hearts from Cav1.2-deficient mice.
Published in: J Biol Chem

Ligand: nitrendipine (Synthetic organic)
Interaction type: Gating inhibitor
Action: Inhibition
Ligand approved: yes
Primary target: yes
Median affinity: 8.399999618530273 pIC50
Reference (Journal): Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms.
Published in: Mol Pharmacol

Ligand: (-)-(S)-BayK8644 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.760000228881836 pEC50

Ligand: [3H](+)-isradipine (Synthetic organic)
Interaction type: Gating inhibitor
Action: None
Ligand approved: no
Median affinity: 9.4 pKd
Reference (Journal): alpha 1D (Cav1.3) subunits can form l-type Ca2+ channels activating at negative voltages.
Published in: J Biol Chem

Ligand: verapamil (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: no
Median affinity: 3.700000047683716 pIC50
Reference (Journal): Effects of phenylalkylamines and benzothiazepines on Ca(v)1.3-mediated Ca2+ currents in neonatal mouse inner hair cells.
Published in: Eur J Pharmacol